Article
Rheumatology
Prateek C. Gandiga, Daniela Ghetie, Elizabeth Anderson, Rohit Aggrawal
Summary: This review provides a practical guide for using intravenous immunoglobulin (IVIG) and subcutaneous immunoglobulin (SCIG) in the management of IIM. IVIG has been proven safe and effective against IIM in recent studies, and it can be used as a first-line or add-on treatment for various types of IIM. However, accessibility and cost remain limiting factors.
CURRENT RHEUMATOLOGY REPORTS
(2023)
Article
Rheumatology
Sangmee Sharon Bae, Ani Shahbazian, Jennifer Wang, Ilana Golub, Buzand Oganesian, Tyler Dowd, Beata Vayngortin, Ryan Wang, David Elashoff, Srinivasa T. Reddy, Christina Charles-Schoeman
Summary: This study found that the activity of PON1 is significantly reduced in patients with IIM compared to healthy controls, and it is inversely associated with disease activity and the presence of severe ILD. The PON1 Q192R polymorphism is strongly linked to the paraoxonase activity of PON1 in IIM, and patients with the PON1 QQ genotype may have better disease outcomes in IIM.
Article
Cardiac & Cardiovascular Systems
Aleksandra Halina Opinc, Marcin Adam Makowski, Zuzanna Malgorzata Lukasik, Joanna Samanta Makowska
Summary: This review provides a detailed study of cardiovascular involvement in idiopathic inflammatory myopathies (IIM), indicating that while such involvement is frequent in IIM, it typically remains subclinical with congestive heart failure being the most common symptomatic form. Further research is needed to investigate the development of cardiovascular diseases and the impact of different treatment options.
HEART FAILURE REVIEWS
(2021)
Review
Medicine, General & Internal
Catherine Ashton, Shereen Paramalingam, Brittany Stevenson, Anna Brusch, Merrilee Needham
Summary: Idiopathic inflammatory myopathy is an umbrella term for various subtypes including dermatomyositis, polymyositis, and necrotising autoimmune myopathy, each presenting with similar clinical features but distinguishable by serum creatine kinase levels and specific muscle involvement. Treatment options are evolving, with focus on diagnosis and therapy based on clinical assessment, serology, and imaging.
INTERNAL MEDICINE JOURNAL
(2021)
Review
Medical Laboratory Technology
Konstantinos I. Tsamis, Constantinos Boutsoras, Evripidis Kaltsonoudis, Eleftherios Pelechas, Ilias P. Nikas, Yannis V. Simos, Paraskevi V. Voulgari, Ioannis Sarmas
Summary: Idiopathic inflammatory myopathies (IIMs) are rare autoimmune disorders primarily affecting muscles, but other organs can also be involved. Recent updates in diagnostic approach, utilizing circulating autoantibodies, have improved patient management.
CRITICAL REVIEWS IN CLINICAL LABORATORY SCIENCES
(2022)
Review
Rheumatology
Rossella Talotta, Irene Porrello, Roberto Restuccia, Ludovico Magaudda
Summary: Idiopathic inflammatory myopathies (IIM) are rare diseases affecting skeletal muscles, and the management of IIM has notably improved in recent years with a better understanding of their pathogenesis. Current therapeutic strategies include pharmacological and non-pharmacological interventions, with physical exercise being an effective option to improve disease activity without worsening muscle inflammation. A combined strategy of aerobic exercise and resistance training can positively impact the pro-inflammatory and metabolic pathways in skeletal muscles, while promoting muscle fiber regeneration and repair.
CLINICAL RHEUMATOLOGY
(2022)
Article
Rheumatology
Leonardo S. Hoff, Fernando H. C. de Souza, Renata Miossi, Samuel K. Shinjo
Summary: This study aimed to evaluate the long-term effects of pulse intravenous methylprednisolone (IVMP) or intravenous immunoglobulin (IVIG) in patients with dermatomyositis (DM) and polymyositis (PM) during the first year of diagnosis. The results showed that patients who received early pulse IVMP or pulse IVMP + IVIG had a higher hazard ratio for complete clinical response, while the combination of pulse IVMP + IVIG was associated with discontinuation of corticosteroids.
Article
Rheumatology
J. C. Milisenda, I Pinal-Fernandez, T. E. Lloyd, J. M. Grau, F. W. Miller, A. Selva-O'Callaghan, L. Christopher-Stine, W. Stenzel, A. L. Mammen, A. M. Corse
Summary: The accumulation of p62 in muscle biopsies is a general response to muscle injury, not specific to sIBM. In sIBM, levels of p62 RNA are decreased, indicating that p62 aggregation in this disease is not due to overexpression.
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY
(2021)
Article
Medicine, General & Internal
R. Aggarwal, C. Charles-Schoeman, J. Schessl, Z. Bata-Csorgo, M. M. Dimachkie, Z. Griger, S. Moiseev, C. Oddis, E. Schiopu, J. Vencovsky, I Beckmann, E. Clodi, O. Bugrova, K. Danko, F. Ernste, N. A. Goyal, M. Heuer, M. Hudson, Y. M. Hussain, C. Karam, N. Magnolo, R. Nelson, N. Pozur, L. Prystupa, M. Sardy, G. Valenzuela, A. J. van Der Kooi, T. Vu, M. Worm, T. Levine
Summary: This study evaluated the use of IVIG for the treatment of dermatomyositis in a randomized, placebo-controlled trial. The results showed that IVIG treatment resulted in a significant increase in the percentage of patients with at least minimal improvement in disease activity compared to placebo. However, IVIG treatment was associated with adverse events, including thromboembolism.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Rheumatology
Salman F. Bhai, Mazen M. Dimachkie, Marianne de Visser
Summary: Idiopathic inflammatory myopathies are a group of systemic inflammatory disorders that primarily affect muscle. Accurate diagnosis requires multiple laboratory and pathological evidence due to the wide variation in signs and symptoms. Misdiagnosis is often attributed to overlapping clinical manifestations and limitations of diagnostic tests. Understanding the limitations of tests and recognizing the shared features between inflammatory and noninflammatory myopathies can help avoid misdiagnosis with other similar conditions.
BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY
(2022)
Review
Clinical Neurology
Adeel S. Zubair, Sharfaraz Salam, Mazen M. Dimachkie, Pedro M. Machado, Bhaskar Roy
Summary: Idiopathic inflammatory myopathies (IIMs) are acquired muscle diseases characterized by muscle inflammation, weakness, and extra-muscular manifestations. Imaging biomarkers such as MRI, muscle ultrasound, EIM, and PET play a crucial role in the diagnosis, assessment, and management of IIMs. MRI is the most commonly used imaging biomarker, but its availability and cost are limitations. Muscle ultrasound and EIM are convenient and can be performed in clinical settings, but further validation is needed. These technologies provide objective assessment of muscle health in IIMs and contribute to improving patient care.
FRONTIERS IN NEUROLOGY
(2023)
Review
Radiology, Nuclear Medicine & Medical Imaging
Khushboo Pilania, Bhavin Jankharia
Summary: Idiopathic inflammatory myopathies are rare autoimmune conditions characterized by slow, progressive muscle weakness and inflammatory infiltrates. The role of MRI in evaluating disease activity and identifying biopsy sites is well-established, but its use in disease phenotyping is less explored.
Article
Medicine, General & Internal
Valerie Leclair, Angeles S. Galindo-Feria, Simon Rothwell, Olga Krystufkova, Sepehr Sarrafzadeh Zargar, Herman Mann, Louise Pyndt Diederichsen, Helena Andersson, Martin Klein, Sarah Tansley, Lars Ronnblom, Kerstin Lindblad-Toh, Ann-Christine Syvanen, Marie Wahren-Herlenius, Johanna K. Sandling, Neil McHugh, Janine A. Lamb, Jiri Vencovsky, Hector Chinoy, Marie Holmqvist, Matteo Bianchi, Leonid Padyukov, Ingrid E. Lundberg, Lina-Marcela Diaz-Galloc
Summary: In patients with idiopathic inflammatory myopathies (IIM), autoantibodies are associated with specific HLA genetic variants and clinical manifestations. Distinct HLA class II and I associations were observed for almost all autoantibody-defined subgroups, supporting the use of autoantibody profiles for classifying IIM.
Article
Rheumatology
Margherita Giannini, Maria Luisa Fiorella, Marilina Tampoia, Francesco Girolamo, Marco Fornaro, Angela Amati, Anna Lia, Letizia Abbracciavento, Dario D'Abbicco, Florenzo Iannone
Summary: This study evaluated the efficacy of a step-up strategy involving IVIG added to immunosuppressants for treating refractory dysphagia in IIM patients. The results showed improvements in dysphagia symptoms after three months of IVIG treatment, with stable or further improvement at the 52-week follow-up. The study also observed improvements in muscle strength and a steroid-sparing effect of IVIG in these patients.
Article
Biochemistry & Molecular Biology
Brunetta Porcelli, Miriana d'Alessandro, Latika Gupta, Silvia Grazzini, Nila Volpi, Maria Romana Bacarelli, Federica Ginanneschi, Giovanni Biasi, Francesca Bellisai, Marta Fabbroni, David Bennett, Claudia Fabiani, Luca Cantarini, Elena Bargagli, Bruno Frediani, Edoardo Conticini
Summary: This study assessed the diagnostic accuracy of anti-cN1A antibodies in patients with suspected IIM and evaluated the agreement between line immunoassay (LIA) and enzyme-linked immunoassay (ELISA). The results showed excellent concordance between LIA and ELISA for detecting anti-cN1A antibodies, suggesting that LIA could be a rapid and useful adjunct, and it could even replace ELISA for cN1A assay.
